WO2023133510A1 - Méthodes de réduction du risque d'accidents cérébrovasculaires par pharmacothérapie pour réduire le nombre et la durée de fibrillations auriculaires - Google Patents

Méthodes de réduction du risque d'accidents cérébrovasculaires par pharmacothérapie pour réduire le nombre et la durée de fibrillations auriculaires Download PDF

Info

Publication number
WO2023133510A1
WO2023133510A1 PCT/US2023/060238 US2023060238W WO2023133510A1 WO 2023133510 A1 WO2023133510 A1 WO 2023133510A1 US 2023060238 W US2023060238 W US 2023060238W WO 2023133510 A1 WO2023133510 A1 WO 2023133510A1
Authority
WO
WIPO (PCT)
Prior art keywords
afib
patient
budiodarone
data
dose
Prior art date
Application number
PCT/US2023/060238
Other languages
English (en)
Inventor
Pascal Druzgala
Peter Gerard Milner
Original Assignee
Xyra, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/978,835 external-priority patent/US11759640B2/en
Application filed by Xyra, Llc filed Critical Xyra, Llc
Publication of WO2023133510A1 publication Critical patent/WO2023133510A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A61B5/683—Means for maintaining contact with the body
    • A61B5/6832—Means for maintaining contact with the body using adhesives
    • A61B5/6833—Adhesive patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/024—Detecting, measuring or recording pulse rate or heart rate
    • A61B5/02416—Detecting, measuring or recording pulse rate or heart rate using photoplethysmograph signals, e.g. generated by infrared radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/024—Detecting, measuring or recording pulse rate or heart rate
    • A61B5/02438—Detecting, measuring or recording pulse rate or heart rate with portable devices, e.g. worn by the patient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/024—Detecting, measuring or recording pulse rate or heart rate
    • A61B5/0245—Detecting, measuring or recording pulse rate or heart rate by using sensing means generating electric signals, i.e. ECG signals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316—Modalities, i.e. specific diagnostic methods
    • A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
    • A61B5/346—Analysis of electrocardiograms
    • A61B5/349—Detecting specific parameters of the electrocardiograph cycle
    • A61B5/361—Detecting fibrillation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A61B5/6802—Sensor mounted on worn items
    • A61B5/681—Wristwatch-type devices

Definitions

  • AFib paroxysmal or persistent atrial fibrillation
  • AFib is a serious medical condition characterized by an abnormal heart rhythm often at accelerated heart rates. Untreated AFib leads to a significant increase in the risk of strokes, congestive heart failure, and death.
  • AFib has been categorized into at least three groups. Patients with intermittent episodes of AFib that last no more than 7 days before returning to normal, either on its own or with treatment, are defined as having paroxysmal AFib. Patients with intermittent episodes of AFib that last for more than 7 days before returning to normal are defined as having persistent AFib. Finally, patients who are constantly experiencing AFib are defined as having permanent AFib.
  • the underlying irregularity of the heart rhythm in AFib results in the accumulation of blood in the upper chambers of the heart.
  • the blood clots cause transient ischemic attacks (TIAs) in the patient.
  • TIAs transient ischemic attacks
  • Such TIAs can cause the patient to feel weakness on one side of the body, slurred speech, or impaired vision which is transitory in nature.
  • the blood clots cause debilitating strokes that can result in anything from a loss of functionality, such as speech or mobility, to a completely comatose state, or death.
  • AFib has been associated with not only an increased risk of stroke but also an increased risk of congestive heart failure - a serious debilitating condition that in the long term is terminal.
  • the risk of stroke and/or congestive heart failure in patients with AFib is significantly higher than in those with a normal heart rhythm, and the risk increases with the duration and number of each episode of AFib (collectively the AFib burden).
  • the recent ENGAGE clinical trial evaluated the risk of stroke for patients, which is set forth in Table 1 below:
  • AFib episodes that last 1 hour or more carry an increased risk of stroke, which increases as the duration of these episodes increases.
  • AFib episodes greater than one hour are designated as “long duration” episodes.
  • Such long duration episodes are divided into two subsets: “medium-long duration” episodes, which are from about 1 hour to about 24 hours or less in duration, and “longer-duration” episodes which are longer than about 24 hours in duration, but not permanent AFib.
  • not all patients suffering from paroxysmal AFib or persistent AFib will evidence long duration AFib.
  • the AFib burden is related to, but distinct from, medium-long or longer-duration AFib.
  • patients with a low AFib burden may experience episodes of long duration AFib, albeit on an infrequent basis.
  • patients with a higher AFib burden may experience multiple short duration episodes of AFib, but little or no long duration episodes.
  • the ability to distinguish between AFib burden and long duration AFib is essential to address the risk of stroke, congestive heart failure, and the like. This is particularly important to an attending clinician who must evaluate the efficacy of pharmacotherapy designed to reduce the number and duration of AFib episodes.
  • AFib Several drugs are designed to treat AFib, including beta blockers and calcium channel blockers. Many of these drugs are designed to control heart rates rather than controlling heart rhythm. However, the risk of stroke is related to extended episodes of AFib, and not the underlying heart rate. Recently, budiodarone (disclosed in US Patent No. 9,549,912, which is incorporated by reference in its entirety) has been shown to control heart rhythm and significantly reduce episodes of long duration AFib. However, because not all patients with AFib evidence episodes of long duration AFib, administration of such a heart rhythm drug to just any patient who experiences AFib is not recommended.
  • clinicians are typically left with only minimal short-term data of up to about 2 weeks regarding a patient’s heart rhythm over this span which is typically used solely for diagnostic purposes rather than assessing the efficacy of a drug that reduces medium-long and longer duration episodes of AFib.
  • limited data can blind the clinician to conditions where sporadic episodes of AFib occur infrequently but are of long duration which can be easily missed using only short-term data.
  • diagnostic devices are not compatible with monitoring and/or pharmacotherapy.
  • Such treatment is designed to reduce or eliminate the risk of stroke or congestive heart failure in a patient evidencing episodes of long duration AFib as well as a threshold level of AFib burden.
  • the methods and devices described herein allow for continuous or semi-continuous monitoring of such a patient's heart rhythm to assess the AFib burden for such patients as well as the duration of such episodes. This allows a clinician to evaluate a patient to determine whether that patient so monitored has a requisite number of episodes of long duration AFib as well as a threshold level of AFib burden.
  • Patients meeting such criteria are deemed “qualified” candidates for starting therapy with budiodarone.
  • Patients already ascertained by conventional means, such as a Holter monitor, as having episodes of long duration AFib and above threshold levels of AFib burden are preferably monitored as above before being placed on budiodarone to assess a baseline number and duration of the episodes of long duration AFib as well as AFib burden to determine whether subsequent pharmacotherapy is efficacious.
  • all qualified patients placed on budiodarone therapy are maintained on monitoring after the start of therapy. Such continued monitoring allows the clinician to evaluate the efficacy of the drug for that patient.
  • the methods disclosed herein provide for pharmacotherapy with budiodarone as a form of personalized medicine where the severity of the disease in a qualified patient is matched with an appropriate dose of budiodarone that is minimally efficacious for that patient - or if the patient is a non-responder, the patient is disqualified from budiodarone therapy.
  • the methods disclosed herein avoid the use of excessive amounts of budiodarone in treating AFib while understanding that some patients require more budiodarone than others to achieve therapy. Still further, the ability to remove a non- responder from therapy represents a new paradigm in treatment by limiting therapy to those patients who are responders.
  • the overall efficacy of budiodarone in one or more patients can be improved by limiting the continued administration of the drug to those patients evidencing a therapeutic result.
  • qualified patients are those who have been previously identified or confirmed to meet minimum thresholds. Qualified patients who show efficacy with budiodarone, either initially and/or after dose adjustments, are continued on the therapy whereas those patients who lack such efficacy (non-responders) are removed from the therapy. Given the variability of the underlying AFib burden as well as the number of long duration AFib episodes in a cohort of patients, budiodarone is efficacious in a significant number of patients, but likely not all patients.
  • the clinician is able to ascertain whether a given patient qualifies for budiodarone therapy and/or whether that therapy is providing efficacious results, thereby allowing the clinician the ability to maintain therapy for only those patients who benefit from budiodarone treatment and at a minimal dose that is needed to achieve efficacious results.
  • the clinician can qualify only those patients with paroxysmal and/or persistent AFib who evidence threshold levels of long duration episodes of AFib and/or AFib burden for treatment with budiodarone. Still further, the clinician can then monitor these patients to assess whether the patient’s AFib is responsive to such treatment or whether dose adjustment of budiodarone is warranted. Finally, the clinician can also remove non-responsive patients from such therapy.
  • Such represents a solution to a long-felt need in the art - namely how to control long-duration AFib to reduce the risk of stroke or congestive heart failure.
  • such qualifying patients can be placed on a national registry that enables the clinician to prescribe budiodarone solely to such registered patients.
  • Patients who show efficacy with budiodarone, either initially and/or after dose adjustments, are retained on the registry, whereas patients who lack such efficacy are removed from the registry.
  • the devices (wearables) described herein address a critical gap in generating the information to allow a clinician to properly evaluate the long-term heart rhythm of a patient, especially as it relates to assessing the patient’s AFib burden and the number and duration of long duration episodes of AFib, before and/or after the start of budiodarone therapy. Still, the continued availability of such information after initiation of therapy allows the clinician to dose-adjust the amount of budiodarone administered to reach a desired therapeutic result at a reduced effective dose (e.g., the minimum effective dose). Still further, these methods and/or devices will elicit patient participation through self-monitoring, which is a well-accepted way of improving patient compliance with their drug regimen. This, in turn, will reinforce the long-term efficacy of any antiarrhythmic drug treatment in reducing or eliminating long-term risks of stroke.
  • a reduced effective dose e.g., the minimum effective dose
  • a wearable is engageable and removable by a patient, who may be diagnosed with or is being evaluated for paroxysmal AFib or persistent AFib.
  • the wearable may comprise and/or be configured to receive data, from at least one electrode and/or optical sensor that, when the wearable is engaged, continuously or semi-continuously monitors the patient’s heart rhythm.
  • the wearable may also alternatively, comprise a processing unit (e.g., a processor, a central processing unit (CPU), a microprocessor, a digital signal processor, a computing device, and the like) that is configured to collect and optionally evaluate the heart rhythm data to determine the presence of and/or the number of long duration episodes of AFib.
  • a processing unit e.g., a processor, a central processing unit (CPU), a microprocessor, a digital signal processor, a computing device, and the like
  • the processing unit mayaltematively, be configured to store the heart rhythm data.
  • the wearable may also, alternatively, comprise a transmission component (e.g., a transmission device) that is configured to access the data in the processing unit (e.g., wirelessly and/or via circuitry' that connects the transmission component and the processing unit).
  • the transmission component may be capable of initiating a communication directly or indirectly to a computing device accessible by the patient and/or a clinician and/or another caregiver of the patient, wherein the communication may provide the heart rhythm data and/or data resulting from evaluating the heart rhythm data.
  • a method for monitoring a patient treated for AFib for one or more long duration episodes of AFib may include engaging an engageable and disengageable wearable.
  • the wearable may comprise at least one electrode or optical sensor that can continuously or semi-continuously monitor a heart rhythm.
  • the wearable may comprise a transmission device and/or circuitry that connects the at least one electrode or optical sensor and the transmission device.
  • the wearable may also alternatively, comprise a CPU that can collect the heart rhythm data, evaluate said data for the presence of long duration episodes of AFib; and store the data.
  • the method may further comprise communicating to the patient and/or the patient’s caregiver the heart rhythm data, which may enable the caregiver to analyze one or more long duration episodes of AFib.
  • a method may be a method for reducing risk of one or more of: transitioning from paroxysmal AFib to persistent AFib in a patient with paroxysmal AFib; transitioning from persistent AFib to permanent AFib in a patient with persistent AFib; or stroke in a patient with AFib, wherein the patient is being treated with budiodarone and the treatment may have reduced and/or inhibited episodes of long duration AFib.
  • the method may include evaluating heart rhythm data collected by a wearable engaged by the patient.
  • the wearable may comprise at least one electrode or optical sensor that can continuously or semi-continuously monitor a heart rhythm.
  • the wearable may comprise a transmission device and/or circuitry that connects the at least one electrode or optical sensor and the transmission device.
  • the wearable may also or alternatively, comprise a CPU that can collect the heart rhythm data, evaluate said data for the presence of long duration episodes of AFib; and store the data.
  • the method may further compri se adjusting the dose of budiodarone to reduce further episodes of long duration AFib (e.g., as deemed necessary by a clinician), thereby reducing the risk of the one or more of a) the transitioning from paroxysmal AFib to persistent AFib, b) the transitioning from persistent AFib to permanent AFib, c) and/or the stroke.
  • a system may comprise a wearable that collects heart rhythm data from a patient diagnosed with either paroxysmal AFib or persistent AFib, a CPU that is in communication with the wearable and that can collect and/or store the data, and a transmission device that can communicate with the CPU and that can send the data to one or more designated recipients.
  • a method may be for reducing the risk of stroke or congestive heart failure in a patient with paroxysmal AFib and/or persistent AFib and being treated with a pharmaceutical.
  • the method may comprise obtaining the patient’s heart rhythm data from a wearable engaged by the patient, wherein the wearable may comprise at least one electrode or optical sensor that can continuously or semi-continuously monitor heart rhythm, a transmission device capable of initiating transmission of data, circuitry connecting the at least one electrode or optical sensor and the transmission device, and a CPU configured to collect and store the heart rhythm data.
  • the wearable is employed prior to treatment with the pharmaceutical (e.g., budiodarone) to obtain baseline data as to the number and duration of AFib episodes.
  • the pharmaceutical e.g., budiodarone
  • the obtained baseline data is used to either qualify or disqualify the patient for treatment with the pharmaceutical.
  • the wearable is employed during treatment with the pharmaceutical where the method comprises or further comprises evaluating said heart rhythm data to determine the effectiveness of the pharmaceutical by correlating the presence and/or absence of episodes of long duration AFib to the dose of the pharmaceutical, determining whether the dose of the pharmaceutical is effective or ineffective in reducing or eliminating episodes of long duration AFib in the patient; and, if ineffective, increasing the dose one or more time, until said dose is effective, thereby reducing the risk of stroke or congestive heart failure.
  • the wearable is programmable (e.g., by a clinician). In one embodiment, the wearable is programmed to transmit all heart rhythm data and/or only that data of long duration episodes of AFib.
  • any episode of AFib that has a duration of at least 1 hour is considered a “long duration” episode.
  • long duration episodes include a subset of episodes that are further defined as being of “medium-long duration”.
  • Such medium-long duration episodes range from at least about 1 hour to no more than about 24 hours.
  • Episodes of AFib that range from more than about 24 hours but are not permanent are categorized as longer-duration episodes. These subsets will allow the clinician to better evaluate the benefits of budiodarone therapy, e.g., when patients with a history of long- duration episodes of AFib transition to experiencing a greater percentage of medium-long duration episodes instead of longer duration episodes.
  • the medium-long duration episodes of AFib range from about 1 hour to about 24 hours, and, in another embodiment, such medium-long duration episodes of AFib range from at least 5 hours up to about 24 hours in duration.
  • a computing device such as a central processing unit (CPU)
  • CPU central processing unit
  • a method to assess whether a patient with paroxysmal or persistent AFib qualifies for budiodarone therapy comprises: a) selecting a patient afflicted with paroxysmal or persistent AFib having an unknown AFib burden and/or unknown number of episodes of long duration AFib over a set period of time; b) fitting said patient with a wearable wherein said wearable comprises: i) at least one electrode and/or optical sensor that, when the wearable is fitted, is continuously or semi-continuously monitoring the patient's heart rhythm; ii) a CPU that collects and stores the heart rhythm data; and iii) a transmission component that connects to the data in the CPU, wherein said transmission component is capable of initiating a communication directly or indirectly to a clinician wherein said data is optionally stored; c) collecting and transmitting the heart rhythm data directly or indirectly to said clinician who evaluates the data for the presence and number of medium-long and/or long- duration episodes of AFi
  • the CPU is also capable of evaluating the stored data to determine the presence and number of medium-long and/or longer-duration episodes of AFib. Evaluation by the CPU can be continuous or periodic. In another embodiment, the CPU can be programmed to alert the clinician and/or patient of medium-long and/or longer-duration episodes of AFib.
  • the patient is fitted with a wearable which can be a patch, a watch, a wristband, a strap, a ring, or any other device that adheres to the body and can operate as described above.
  • the wearable should be engaged on the patient except for a period of temporary disengagement such as for showering, swimming, changing batteries, etc.
  • a method to assess if a qualified patient on budiodarone therapy should be dose adjusted or disqualified comprises: a) selecting a patient qualified for and is prescribed for treatment with budiodarone by a clinician wherein said patient is fitted with a wearable wherein said wearable comprises: i) at least one electrode and/or optical sensor that, when the wearable is fitted, continuously or semi-continuously monitors the patient's heart rhythm; ii) a CPU that collects and stores the heart rhythm data; and iii) a transmission component that connects to the data in the CPU, wherein said transmission component is capable of initiating a communication directly or indirectly to a clinician wherein said data is optionally stored; b) collecting and transmitting the heart rhythm data directly or indirectly to said clinician where the data is evaluated for the presence and number of long duration episodes of AFib and the extent of AFib burden; c) optionally adjusting the dosing of budiodarone to access which dose is appropriate for
  • patients who are initially responsive to budiodarone therapy are continuously or periodically monitored to ensure that each of said patients remains responsive to the dose of budiodarone. If not, the clinician can adjust the dose of budiodarone or discontinue budiodarone therapy as appropriate.
  • the data is transmitted directly or indirectly to the clinician who can assess the presence or absence of medium-long and/or longer- duration AFib, and optionally the extent of AFib burden.
  • the data can be stored and/or analyzed at a central analysis center, such as a “cloud” laboratory or similar site (such as a CORE laboratory), where a qualified health care professional can analyze the data and advise the attending clinician as to the patient’s response and recommended adjustments to the therapy.
  • a central analysis center such as a “cloud” laboratory or similar site (such as a CORE laboratory)
  • a qualified health care professional can analyze the data and advise the attending clinician as to the patient’s response and recommended adjustments to the therapy.
  • RPM remote patient monitoring
  • the requisite number of long duration AFib episodes and requisite extent of AFib burden to qualify for budiodarone pharmacotherapy may comprise one or more of long duration AFib episodes (e.g., at least a threshold number) of one or more minimum lengths (e.g., at least 1 hour, at least 5 hours, at least 24 hours, etc. and any one hour period between 1 hour and 24 hours) over a time period (e.g., over two weeks, a month, two months, etc.).
  • long duration AFib episodes e.g., at least a threshold number
  • minimum lengths e.g., at least 1 hour, at least 5 hours, at least 24 hours, etc. and any one hour period between 1 hour and 24 hours
  • a time period e.g., over two weeks, a month, two months, etc.
  • the requisite number of long duration AFib episodes may comprise at least one episode of AFib lasting more than 5 hours over a month and/or at least two episodes of AFib lasting more than 1 hour over a month.
  • a requisite extent of AFib burden may be at least a minimum extent of AFib burden (e.g., 0% - no required AFib burden, 1%, 2%, etc.).
  • the requisite number of long duration AFib episodes and requisite extent of AFib burden may be set as is appropriate. Specific examples as part of a non-exhaustive list are provided in Table 2 below:
  • the wearable may comprise a storage unit for storing collected data, and the storage unit can be programmed to evaluate the stored data and alert the clinician or central analysis center of any potentially harmful heart rhythm irregularities.
  • the collected and/or evaluated data may be continuously or periodically reviewed by the clinician or health care professional (e.g., may be pushed to a computing device accessible by the clinician continuously or periodically, and/or pulled based on a request by the computing device accessible by the clinician).
  • Periodic evaluation can be, for example, once a day, once a week, twice a month, once a month, etc.
  • the data collection process may be continued indefinitely, e.g., until the clinician determines that the patient’s heart rhythm data either meets or fails to meet the requisite number of episodes of long duration AFib and/or the requisite extent of AFib burden.
  • data collection continues for at least 14 days, 30 days, 45 days, 2 months, or at least 12 weeks, or at the discretion of the attending clinician based on the history and risk factors of the patient. Patients who fail to meet established criteria for qualification are not included in budiodarone therapy.
  • qualified patients are placed on budiodarone therapy.
  • Such therapy includes the administration of budiodarone or a pharmaceutical composition comprising budiodarone twice a day (b.i.d.) in an amount ranging from about 200 mg b.i.d. to about 800 mg bid.
  • the preferred dosing includes an escalating amount of budiodarone where the patient is initially dosed at 200 mg budiodarone b.i.d. Responsive patients remain on that dose whereas non-responsive patients are dose adjusted in 200 mg increments until the patient either becomes responsive or the patient is non-responsive at all tested dose levels. In the latter case, the patient is disqualified from budiodarone therapy.
  • the qualified patients so treated are refractory to one or more other methods for treating their AFib leaving the methods described herein as a remaining option for treatment.
  • the serum half-life of budiodarone is about 6 to 7 hours after administration.
  • a steady state concentration of a drug is about 5x the serum half-life. In this case, the steady state would be about 30 to 35 hours.
  • the wearable can be a watch, a strap, a wrist band, a ring, or a strap.
  • the watch is a smart watch.
  • a method for reducing the risk of a patient progressing from paroxysmal AFib to persistent AFib or from persistent AFib to permanent AFib comprises: identifying a patient with either paroxysmal or persistent AFib having an AFib burden of at least 2.5% coupled with at least one episode of long duration AFib over a 4- week period; administering an initial dose of budiodarone to said patient; monitoring the efficacy of said administration and optionally adjusting the dose of budiodarone at least once for the patient as needed to achieve a reduction in either or both AFib burden and long duration AFib whereupon the risk of progression from paroxysmal AFib to persistent AFib or from persistent AFib to permanent AFib is reduced in the patient; and maintaining said monitoring to
  • a method for reducing the risk of heart failure in a patient diagnosed with paroxysmal AFib or persistent AFib comprises: identifying a patient with either paroxysmal or persistent AFib having an AFib burden of at least 2.5% coupled with at least one episode of long duration AFib over a 4- week period; administering an initial dose of budiodarone to said patient; monitoring the efficacy of said administration and optionally adjusting the dose of budiodarone at least once as needed to achieve a reduction in either or both AFib burden and long duration AFib whereupon the risk of heart failure in said patient is reduced; and maintaining said monitoring to confirm the continued efficacy of budiodarone.
  • a method for reducing the risk of stroke in a patient diagnosed with paroxysmal AFib or persistent AFib comprises: identifying a patient with either paroxysmal or persistent AFib having an AFib burden of at least 2.5% coupled with at least one episode of long duration AFib over a 4- week period; administering an initial dose of budiodarone to said patient; monitoring the efficacy of said administration and optionally adjusting the dose of budiodarone one or more times as needed to achieve a reduction in either or both AFib burden and long duration AFib whereupon the risk of stroke in said patient is reduced; maintaining said monitoring to confirm the continued efficacy of budiodarone.
  • a method for reducing the risk of stroke or congestive heart failure in a patient with paroxysmal AFib or persistent AFib wherein said AFib is treated with a pharmaceutical which method comprises: a clinician obtaining a patient’s heart rhythm data from a wearable engaged by the patient wherein said wearable comprises a) at least one electrode or optical sensor that continuously or semi-continuously monitors heart rhythm; b) a transmission device capable of initiating transmission of data; c) circuity that connects the two; and d) a CPU that collects and stores the heart rhythm data, said clinician conducts an evaluation of said data to determine the effectiveness of the pharmaceutical by correlating the presence or absence of episodes of long duration AFib to the dose of the pharmaceutical used; said clinician confirms that the dose of the pharmaceutical is effective or ineffective in reducing or eliminating episodes of long duration AFib; and if ineffective, said clinician increases the dose of the pharmaceutical one or more times until said dose is effective thereby reducing the risk of stroke or congestive
  • a method for reducing the risk of stroke or heart failure in a patient diagnosed with AFib and treated with budiodarone which inhibits episodes of long duration AFib in said patient comprises: evaluating the patient’s heart rhythm data collected by a wearable and transmitted to said clinician from a wearable engaged by said patient wherein said wearable comprises: a) at least one electrode or optical sensor that continuously or semi- continuously monitors heart rhythm; b) a transmission device; c) circuitry that connects the two; and d) a CPU that i) collects the heart rhythm data and may evaluate said data for the presence of long duration episodes of AFib; and ii) stores the data; and evaluating said data to determine the effectiveness of the pharmaceutical by correlating the presence or absence of episodes of long duration AFib to the dose of the pharmaceutical used; confirming that the dose of the pharmaceutical is effective or ineffective in reducing or eliminating episodes of long duration Aib; and adjusting the dose of budiodarone as deemed necessary
  • FIG. 1 illustrates a chart indicating how the patient’s AFib data is used in conjunction with treatment with budiodarone
  • FIG. 2 illustrates a cardiogram of a patient with intermittent AFib.
  • This disclosure is directed to methods for monitoring the heart rhythm of patients diagnosed with atrial fibrillation (AFib). Such monitoring allows for therapeutic intervention coupled with the ability to modulate the dosing of the pharmaceutical employed to obtain therapeutic end points that reduce the risk of stroke and/or heart failure.
  • AFib atrial fibrillation
  • the term “optional” or “optionally” means that the subsequently described event or circumstance may or may not occur and that the description includes instances where the event or circumstance occurs and instances where it does not.
  • the term “about” when used before a numerical designation, e.g., temperature, time, amount, concentration, and such other, including a range, indicates approximations which may vary by (+) or (-) 15%, 10%, 5%, 1%, or any subrange and/or value there between.
  • the term “about” when used with regard to a dose amount means that the dose may vary by +/- 10%.
  • compositions or methods are intended to mean that the compositions or methods include the recited elements, but do not exclude others.
  • compositions and methods when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination for the stated purpose.
  • AFib or “atrial fibrillation” refers to all variants of atrial fibrillation except permanent AFib. Such variants include but are not limited to paroxysmal AFib, persistent AFib, as well as paroxysmal AFib and persistent AFib with low CHA2DS2- VASc scores (2 or less) and high CHA2DS2-VASc scores (3 or higher).
  • CHA2DS2-VASc scores stand for congestive heart failure, hypertension, age ⁇ 75 (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74, and sex category (female) and are clinical prediction rules for estimating the risk of stroke in people with non-rheumatic atrial fibrillation (AF).
  • a CHA2DS2-VASc score comprises a point for each of the constituent risk factors, or 2 points were indicated as (doubled).
  • a long duration AFib relates to the length of time an episode of AFib lasts in a patient. This length relates to the risk of stroke and/or heart failure. As is apparent, the longer the length of time a patient is in AFib, the higher the risk becomes. So, in one embodiment, a long duration AFib is any AFib episode lasting over 1 hour, provided that the AFib is not permanent.
  • long duration AFib is further categorized by the subsets “medium-long duration” AFib, which is about 24 hours or less in duration (i.e., over 1 hour and up to 24 hours) and “longer-duration” AFib, which includes AFib episodes of over 24 hours, but which are not permanent AFib.
  • continuous refers to monitoring conducted constantly during the engagement of a wearable by the patient. Included within the term “continuous” or “continuously” are wearables that constantly monitor the heart rhythm when worn and powered, but which may be taken off for limited periods of time (e.g., changing batteries, bathing, etc.).
  • the term “semi-continuous” or “semi-continuously” refers to monitoring that is automatically done periodically by the wearable on a set schedule (e.g., every 15 seconds, every 30 seconds, every minute, and the like) without the patient’s activation of the wearable.
  • the set schedule a schedule designed to be able to monitor heart rhythm with a temporal resolution sufficient to detect AFib episodes and/or to allow determination of lengths of long duration AFib episodes.
  • engageable means that the patient can place the wearable on and off his/her body and initiate monitoring without the need for assistance from an attending health care professional. As such, engageable wearables do not include implanted (invasive) devices such as pacemakers.
  • monitoring the heart rhythm means any evaluation that can be made of a patient’s heart rhythm including the pulse rate, any aspect of the electric field of the patient’ s heart, and the like provided that such monitoring is capable of ascertaining when the patient is experiencing AFib.
  • the term “initiate monitoring” includes both automatic initiation and physical initiation. “Automatic initiation” occurs when the wearable, once placed on the patient, automatically starts monitoring without any further action by the patient. “Physical initiation” means that the patient is required to activate the monitoring by physically or verbally interacting with the wearable (e.g., pushing a button, providing a voice command, and the like).
  • the term “transmission device” means any device capable of transmitting data from the wearable.
  • the transmission device may be included in the wearable or may be a separate device that is in communication with the wearable.
  • the separate device can be a smart phone, a computer such as a pad, a laptop, a desktop, and the like.
  • the term “clinician” refers to a healthcare professional qualified to ascertain whether a patient’s heart rhythm data correlates to sinus rhythm, atrial fibrillation, or other types of arrhythmias.
  • attending clinician refers to the healthcare professional who is treating the patient with AFib. Such an attending clinician is typically a doctor or a nurse practitioner.
  • heart rhythm data refers to a transmission that is received by the attending clinician for evaluation regardless of whether the transmission was deposited in a Cloud site or through a number of servers, etc.
  • the term “indirectly” as it relates to the transmission of the patient’s heart rhythm data refers to transmission to a clinician who evaluates the data and provides either the data or the conclusions reached regarding the data to the attending clinician or a health care provider.
  • the clinician can be a healthcare professional employed by a central analysis center or by the attending clinician, etc. to evaluate the heart rhythm data and provide instructions to the attending clinician either on an ongoing basis or when a change in the patient’s condition warrants contact.
  • the clinician is employed by a central analysis center, a facility that reviews the data generated by its instruments and renders a diagnosis and/or recommendation that is transmitted to the attending clinician.
  • the central analysis center has expertise in the instrument, the data generated, and the ability to analyze that data.
  • a patient who is “responsive to budiodarone therapy” evidences a reduction in the number and/or duration of episodes of long duration AFib.
  • the reduction may be a reduction by at least a certain percentage (e.g., at least 10%, preferably at least 20%, more preferably at least 30%, more preferably at least 40%, more preferably at least 50%, etc.) of one or more of the number of episodes of long duration AFib episodes and/or the duration of episodes of long duration AFib.
  • a responsive patient is a patient that evidences at least a 10% reduction in at least one of the following when measured over a 12-week period: a) the number of long duration episodes of AFib lasting over 24 hours as compared to the number determined during qualification; b) the number of long duration episodes of AFib lasting over 5 hours as compared to the number determined during qualification; c) the number of long duration episodes of AFib lasting over 1 hour as compared to the number determined during qualification; or d) a reduction in AFib burden as compared to the burden determined during qualification.
  • the responsive patient exhibits at least a 20% reduction, at least a 30% reduction, at least a 40% reduction, at least a 50% reduction, and/or at least a 60% reduction in one or more of a-d above over a 12 week period.
  • a “non-responsive patient” or patient who is “non-responsive to budiodarone therapy” is a patient that has been treated with budiodarone therapy and does not meet the definition of a responsive patient, as defined above.
  • a patient may be non- responsive to a maximum allowable dosage, thereby being non-responsive to budiodarone therapy and the therapy stopped.
  • other methods to treat AFib may comprise one or more blood thinners and/or other clot prevention measures, heart rate control measures, and/or heart rhythm control measures.
  • Examples of such methods to treat AFib may include beta blockers (e.g., atenolol, bisoprolol, carvedilol, metoprolol, propranolol, timolol), Calcium channel blockers (verapamil, diltiazem), blood thinners (warfarin, coumarin, Jantoven, aspirin, apixaban, dabigatran, enoxaparin, heparin, rivaroxaban), sodium channel blockers (e.g., flecainide, propafenone, quinidine), potassium channel blockers (e.g., amiodarone, dofetilide, sotalol).
  • beta blockers e.g., atenolol, bisoprolol, carvedilol, metoprol
  • a patient may be deemed “refractory to one or more prior methods to treat their AFib” or “refractory to one or more other methods to treat their AFib” if they have been treated with the one or more prior and/or other methods to treat AFib (e.g., the other methods to treat AFib, as defined above), and their AFib has been deemed unresponsive and/or insufficiently responsive, and/or of decreasing responsiveness to the one or more methods.
  • the “one or more prior therapies” may be ongoing and/or may have been terminated.
  • smart refers to the computational capabilities of a device.
  • the computational abilities of smart devices discussed herein may allow for user interaction (e.g., via a touchscreen) and/or for running applications on the smart device.
  • an AFib burden of at least 2.5% means that in the absence of therapy according to the present disclosure (e.g., treatment with budiodarone and/or other heart rhythm drug), the patient has episodes of AFib where the aggregate of the duration of each episode over a set period of time is at least 2.5% of the total amount of time in said set period. So, for a patient monitored for 20 days (or 480 hours), at least 2.5% AFib burden means that the total (cumulative) period of time where the patient experiences one or more episodes of AFib is at least 12 hours (2.5% of 480 hours). This AFib burden may be independent of the number, if any, of episodes of long duration AFib. As such, the one or more episodes of AFib that in the aggregate total at least 12 hours can be a single episode or many episodes of less than 1 hour each.
  • the term “budiodarone” refers to (S)-sec-butyl2-(3-(4-(2-(diethyl amino)ethoxy)-3,5-diiodobenzoyl)benzofuran-2-yl)acetate as well as pharmaceutically acceptable salts thereof.
  • Budiodarone is represented by the following formula: as well as pharmaceutically acceptable salts thereof, e.g., budiodarone tartrate or budiodarone citrate.
  • the pharmceutically acceptable salt may be other polycarboxylic salt. As is appreciated in the art, the salt disassociates from the free base in vivo.
  • the molecular weight of the free base is used to determine molarity.
  • the dose of budiodarone tartrate salt that is used herein will necessarily be changed to reflect the molecular weight change due to the different salt.
  • a wearable device refers to any device that can be worn by a user, e.g., as an accessory, as clothing and/or embedded in clothing, etc.
  • a wearable device herein may be capable of measuring the heart rhythm of a user thereof without implantation (such as surgical and/or subcutaneous implants).
  • a patient is “fitted with a wearable” when the wearable is being worn by, or is otherwise fixed to, the patient so as to be able to measure the heart rhythm of the patient.
  • baseline refers to a patient who has AFib and is monitored to determine the extent of AFib burden and the number of episodes of long duration AFib over a set period of time prior to treatment with budiodarone. In such a case, measuring the baseline prior to therapy over a set period of time provides for the current state of the disease. In most if not all cases, the baseline state of the disease is unknown to the attending clinician and is necessary information to determine if subsequent treatment with budiodarone is effective.
  • the instrumentation used in the methods described herein may be used for pharmacotherapy as described herein, as opposed to merely for diagnosis.
  • Using wearables merely for diagnosis is conventional and aims to inform the clinician whether the patient either has AFib or not and/or, if the patient has AFib, possibly information about the patient’s AFib burden and the number of episodes of AFib.
  • diagnostic analysis fails to address any pharmacotherapeutic suitability, efficacy, and/or dose, which extends beyond diagnosis.
  • the pharmacotherapeutic methods described herein include identifying patients who qualify for drug therapy and/or monitoring the qualified patient during treatment with the pharmacotherapy to assess the drug’s effectiveness (e.g., in reducing the number of episodes of long duration AFib).
  • the monitoring may allow for dose adjusting for the patient until the patient is deemed to be responsive to therapy or is disqualified from pharmacotherapy due to a failure to respond.
  • the pharmacotherapeutic methods described herein may provide for limited (e.g., one or more periods of a discrete period, such as a period of about two or four, or six weeks) and/or indefinite (e.g., without a preset end-date) monitoring of the patient to establish qualification for drug intervention and/or to ensure that the patient is and/or remains responsive. Accordingly, the wearables described herein are designed and/or selected to be robust for extended use, and/or comfortable and/or easy to use by the patient.
  • the wearable may include a cardiac monitoring component, which may be either an assisted or an unassisted component, for measuring heart rhythm in patients.
  • the wearable may be engageable and removable by the patient and do not involve invasive procedures common to non-wearables, such as pacemakers, implantable cardioverter defibrillators (ICD), and the like.
  • the specific cardiac monitoring component employed in the wearable is not critical, provided it can accurately measure the heart rhythm.
  • the wearable may be capable of reporting measured heart rhythm data, such as by generating and/or transmitting data indicating a length of time of a detected period of AFib, and/or by generating and/or transmitting data indicating a number of episodes of long duration AFib detected (e.g., over a time period of interest, such as a week, a month, etc.). Also, or alternatively, the wearable may be configured to transmit heart rhythm data to a device configured to detect AFib and/or determine a length of time of a detected period of AFib and/or a number of episodes of long duration AFib (e.g., over the time period of interest).
  • the wearable is approved by one or more regulatory bodies, such as the US Food & Drug Administration (FDA).
  • An assisted cardiac monitoring component may use photoplethysmography (PPG) to detect heart rate and rhythm.
  • PPG is a conventional technology found in standard oximeters, measures light reflection in tissue to detect arterial pulsations and, accordingly, heart rhythm patterns.
  • an algorithm may be used to reduce enough of the distortion and/or noise to provide for a reliable signal.
  • both a PPG sensor and accelerometer are employed with an algorithm that allows for appropriate (e.g., sufficient signal to noise ratio). When so assisted, PPG may allow for a reliable detection of both heart rates and heart rhythm.
  • the cardiac monitor component uses piezoelectric material and/or rhythm electroactive polymers to detect blood flow, thereby indirectly measuring heart rhythm.
  • a combination of PPG and/or piezoelectric measurements and electrocardiogram data from single-electrode wearables can be combined in order to increase the specificity of the measurement.
  • the iECG and the PPG or the piezoelectric data can originate either from two separate devices communicating by transceivers, for example, an armband and a smartwatch, or they can originate from a single device, for example, a wrist band on a smartwatch (for example, the Kardia Band on an iWatch).
  • the corresponding (e.g., in time) iECG data may be analyzed by an algorithm.
  • the wearable may include an unassisted cardiac monitor component, such as a portable electrocardiogram.
  • the portable electrocardiogram component may be wearable, engageable at will by the patient, and/or capable of transmitting data, e.g., via a built-in antenna.
  • the wearable comprising the unassisted cardiac monitor component can measure heart rates and heart rhythms.
  • the wearable may be configured to detect and log AFib burden and/or long duration (episode) of AFib (LEAF) over an observation period (e.g., of about 2 weeks or longer).
  • the unassisted cardiac monitor component employs direct measurement, which means that the device is reading electrical signals generated by the heart.
  • the direct measurement may be less affected by noise and distortion than indirect measurements, such as PPG measurements, which may enable transmitting measurement data to a clinician without the use of an algorithm, and/or with reduced use of any algorithm or data processing.
  • the wearable may include a specialized accessory, such as a cardiac monitor device, that can detect the electrical activities of a heart including heart rhythm through an electrode.
  • the specialized accessory may be capable of initiating transmission and/or may comprise and/or be connected to a transmission device.
  • the cardiac monitor device can be a component that is an integral part of a single wearable device, such as a smartwatch.
  • a single wearable device such as a smartwatch.
  • the cardiac monitor device may include an analog-to-digital convertor capable of digitalizing measured electric field data (e.g., measured potential difference data) to transmit and/or stored in memory the measured data as digitized data.
  • the cardiac monitor device can include an output that can transmit signals carrying information about the difference of potential between the limb and the body to an external circuit.
  • the output can take various forms. In one case, the output can be a transceiver that communicates to another transceiver/receiver in another unit, for example, a watch or a tablet.
  • a central analysis center e.g., a remote lab, such as a CORE lab and/or a remote data analysis center and/or a server
  • the central analysis center may interpret and/or summarize the AFib data and/or the LEAF data.
  • the central analysis center may also transmit a dose adjustment recommendation to the treating clinician, without a need for the patient to visit his or her physician (e.g., as part of a patient monitoring program).
  • an artificial intelligence algorithm may be used to determine the dose adjustment, and may transmit the dose adjustment recommendation to the physician.
  • the wearable may be a small consumer electronic device, for example, a watch, an armband, a ring, a strap, and/or a wristband.
  • the wearable may include a housing that carries the cardiac monitor component and any associated circuitry, CPU, and the like.
  • the wearable can also be worn at other locations on the user, including, but not limited to, the wrist, leg, neck, and/or body.
  • the wearable may comprise a specialized accessory capable of communicating with another electronic device such as a tablet, a laptop computer, a desktop computer, and/or other similar devices, which, in turn, can communicate to a cloud network to transmit information from the device to the clinician.
  • the specialized accessory may be capable of transmitting information directly and/or via a network to the clinician.
  • the heart rhythm and iECG wearables may be Bluetooth, Z-Wave, Zigbee, and/or Advanced and Adaptive Network Technology (ANT)-enabled.
  • the iECG and/or the heart rhythm monitoring and/or recording device e.g., a PPG or piezoelectric heart rhythm monitoring and/or recording device
  • the iECG device and/or the rhythm monitoring and/or recording device may be configured to transmit data to the application.
  • the data may be transmitted using one or more of Bluetooth, Z-Wave, Zigbee, or ANT protocols.
  • the application may be configured to analyze the data using a proprietary software. Based on the data from the iECG and/or the heart rhythm monitoring and/or recording device, the application may be able to interpret and/or detect AFib with a sensitivity >90% and a specificity >80%.
  • Patients with a wearable as described herein can use the wearable to record heart rhythm and detect AFib.
  • the recording can be continuous and/or semi-continuous.
  • the specifics of the recording can be programmed into the device, directly or indirectly (e.g., remotely).
  • AFib data may be stored securely, such as in a cloud-based data repository using highly secured protocols.
  • Examples of commercially available assisted and unassisted wearables include, without limitation, the following: * MCOT® wearables sold by Philips Biosciences, Best, Netherlands.
  • This device is a wearable patch that can send iECG data automatically via a wireless connection to a central analysis center (e.g., a CORE lab).
  • This system is configured to provide data sufficient to enable a clinician to determine if dose escalation and/or drug discontinuation is warranted.
  • An ePatch extended wear Holter monitoring system sold by Philips Biosciences, Best, Netherlands. This device is configured to record data indicating AFib and/or long duration (episode) of AFib (LEAF). This device is configured to record and/or store iECG data continuously. This data is then archived and analyzed centrally.
  • wearables there are a number of other wearables, some of which are FDA approved, which can be used in placed of those recited above including, by way of example only, Zio by iRhythmtech, San Francisco, California, USA; Frontier X2, Fourth Frontier, Austin, Texas, USA, wearables by VivaLink, Campbell, California, USA, just to name a few.
  • the above and other wearables discussed herein represent a non-exhaustive list of wearables suitable for use in the methods described herein.
  • the specific wearable to be used is not critical, as long as it is capable of measuring heart rhythm (e.g., generating a signal and/or data from which heart rhythm can be determined).
  • the wearable used should be capable of measuring the heart rhythm of a patient fitted with the wearable continuously or semi-continuously for a required time period as described herein (e.g. a required time period for determining a baseline, for monitoring during pharmacotherapy, etc.). Further, the wearable should be small enough and/or comfortable enough for a patient to wear and/or be fitted with the wearable for the required time period.
  • the disclosed methods allow the attending clinician to identify and/or treat a qualified patient with pharmacotherapy, as well as to assess the efficacy of the therapy based on heart rhythm data monitored over a period of time.
  • the period of time may be an extended period of time, which may be measured in weeks, months, and/or years.
  • the monitoring may comprise monitoring heart rhythm data and/or using said heart rhythm data to determine a condition of the patient’s AFib, which may be determined based on one or more of the patient’s AFib burden or the number or duration of AFib episodes over the period of time (e.g., a frequency of AFib episodes and/or long duration AFib episodes).
  • conventional monitoring of a patient is typically diagnostic in nature, e.g., conducted during a single short-duration period typically of no more than two- weeks using a Holter monitor or the equivalent.
  • diagnostic methods allow the clinician to at best confirm the presence of AFib. In most cases, the clinician will then place the patient on blood thinners.
  • the clinician can place a diagnosed patient on pharmacotherapy, which might involve heart rate reduction using beta-blockers and/or calcium channel blockers. Regardless, once diagnosed, conventional monitoring is typically terminated.
  • the methods described herein are directed at treating the patient’s heart rhythm to reduce the causative reasons for stroke and heart failure.
  • the clinician can significantly reduce the risk of stroke or congestive heart failure.
  • the clinician can now evaluate the efficacy of the drug, adjust the dose as needed to enhance overall efficacy, or identify those patients who are non-responders to such therapy who are removed from the therapy.
  • FIG. 1 schematizes an iterative process to evaluate a patient, qualify a patient for budiodarone therapy, and treat the qualified patient.
  • FIG. 1 an exemplary cohort of patients, who have been diagnosed with either paroxysmal and/or persistent AFib, are evaluated for their AFib burden.
  • the patients may also be evaluated for the duration of their AFib episodes.
  • patients are further qualified for budiodarone therapy (“Yes” at star decision point) if there is evidence of at least 1 episode of AFib lasting more than 5 hours over a 1 -month period and/or two or more episodes of AFib lasting more than 1 hour over a 1 -month period.
  • Patients who fail to meet either of these criteria are excluded (“No” at star decision point) as presumably having a very low risk of stroke or congestive heart failure.
  • Qualified patients are placed on an ascending dose regimen of budiodarone, which has been shown to significantly reduce episodes of AFib, including episodes of long duration AFib, which, by definition, reduce AFib burden.
  • Other drugs that behave similarly to budiodarone may be used in place of and/or in addition to budiodarone in the methods described herein.
  • an ascending regimen is employed to assess whether budiodarone is effective in treating long duration episodes of AFib and/or at what dose(s).
  • AFib burden and/or the number and duration of episodes of long duration AFib vary from patient to patient, different doses of budiodarone may be effective for different patients.
  • a clinician prescribing budiodarone at a first dose was blinded from whether that dose was efficacious. As per FIG.
  • the methods described herein allow the clinician to assess efficacy at a first dose and/or to dose adjust in an ascending and/or descending protocol in an iterative process until either a therapeutic result is achieved, and/or the patient is deemed to be a non-responder. As to such non-responders, they are removed from budiodarone therapy.
  • an ascending regimen patients are first administered a low dose and may have the dose increased in case the patient is non-responsive and/or insufficiently responsive (e.g., “No” at the plus signs). A patient may be determined non-responsive if they do not respond to a maximum dosage.
  • a descending regimen can also, or alternatively, be employed, in which a highest dose of budiodarone is administered to the patient and efficacy is determined for decreasing dosages.
  • One advantage of a descending protocol is that non-responders could be determined in the first iteration and not the last.
  • an ascending protocol may have benefits of first finding a lowest effective dosage and/or reducing the risk of sideeffects.
  • treatment of a patient with budiodarone may result in reducing a number and/or frequency of episodes of long duration AFib and/or may result in reducing the AFib burden. This is in contrast to drugs that reduce heart rate but have little to no ability to reduce the duration AFib episodes and/or the AFib burden.
  • AFib burden and episodes of long duration AFib are distinct.
  • AFib burden the number and duration of each AFib episode in a patient is measured to determine an AFib burden.
  • a patient with a enough of only very short duration episodes of AFib may still be assigned a higher AFib burden than a patient with infrequent episodes of long duration AFib.
  • a patient who has 8 episodes of AFib each having a duration of 45 minutes in a given 24-hour period would be assigned a AFib burden of 25% (6 hours/24 hours).
  • a patient with a single episode of AFib lasting for 5 hours during a 24-hour period would be assigned an AFib burden of 20.8%.
  • the latter patient with the single AFib episode may be at greater risk of a stroke than the former patient. Accordingly, patients having an AFib burden of less than 2.5% are very unlikely to have long duration AFib and, accordingly, may be determined not qualified for treatment with budiodarone.
  • transitioning a patient from either paroxysmal AFib to persistent AFib or from persistent AFib to permanent AFib may be undesirable as it may evidence unwanted disease progression. Because budiodarone reduces the extent of long duration AFib and the number of AFib episodes, the combination of these reductions inhibits the progression of the disease and, in some cases, may revert such a transition.
  • AFib Treatment of AFib with blood thinners does not address the cause of AFib, does not reduce the underlying concerns with either AFib burden and/or with episodes of medium duration and longer-duration AFib. Moreover, using blood thinners does not prevent a patient from progressing from paroxysmal AFib to persistent AFib or from persistent AFib to permanent AFib. Still further, the use of blood thinners introduces another set of issues with bleeding, such as bleeding that leads to death. [0101] In view of the above, according to the present disclosure, a patient’s heart rhythm may be monitored over an extended period to assess the efficacy of a drug that is intended to control such long duration episodes.
  • Devices such as a Holter monitor can be used to monitor a patient’s heart rhythm over a short period of time (e.g., 1 day, 2 days, or 3 days and even up 14 days), but such monitoring cannot provide a comprehensive and ongoing analysis of the patient’ s AFib and/or how a drug treatment is impacting the number and duration of episodes of AFib over extended periods of time (e.g., of weeks or more).
  • Such short-duration analysis provides only a diagnostic analysis, not a therapeutic analysis, and fails to provide a full picture of the heart health of the patient. Due to the erratic and dynamic nature of AFib, and variability across patients, an accurate measurement of AFib in a patient can only be obtained by monitoring over prolonged periods of time, such as longer than 1 month, longer than 3 months, etc.
  • hemoglobin A1C also referred to as HbAlC test is a blood test
  • HbAlC test is a blood test
  • liver function, prostate health, thyroid health, etc. can all be evaluated based on a specific number that provides meaningful information to the clinician.
  • the clinicians treating paroxysmal and/or persistent AFib have had to rely upon brief monitoring of the patient’s heart rhythm, such as an ECG (electrocardiogram) and/or a Holter monitor.
  • brief monitoring may miss critical data points that could only be obtained by monitoring over longer periods of time. This may cause a clinician to avoid pharmacotherapy without a means to monitor the drug’s effectiveness in the patient.
  • a patient diagnosed with AFib may be placed on symptom and/or risk reduction treatments, such as blood thinners.
  • blood thinners will reduce the risk of clot-related strokes (e.g., clots arising from AFib), there is a corresponding increased risk of uncontrolled bleeding which can lead to death.
  • sotalol as well as beta-blockers and calcium channel blockers
  • calcium channel blockers include amlodipine, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, and verapamil.
  • beta blockers include acebutolol, atenolol, bisoprolol, metoprolol, nadolol, nebivolol, and propranolol.
  • Drugs with combined modes of action, such as amiodarone also exist.
  • Amiodarone has a long half-life and its accumulation after chronic use is associated with a wide variety of toxicities including lung, liver, and ocular effects; its use requires close supervision of recipients to detect early signs of irreversible and potentially fatal complications [see, e.g., Wolkove N, Baltzan M., “Amiodarone pulmonary toxicity,” Canadian Respiratory Journal 16(2): 43-8 , 2009].
  • Budiodarone a drug with a combined mode of action, has been shown to reduce episodes of long duration AFib without a significant increase in the QT interval.
  • Budiodarone has a pattern of cardiac ion channel effects that by design, are like amiodarone with enhanced late Na + channel blockade.
  • Budiodarone’ s deliberately altered metabolism results in a much shorter half-life than amiodarone, however, enabling the avoidance of accumulation-related toxicities seen with amiodarone and complete inactivation and elimination from the body within hours to days of discontinuation.
  • budiodarone represents a significant advancement in treatment for AFib, since episodes of long duration AFib are substantially the cause of clot formation that may lead to strokes and/or congestive heart failure.
  • AFib is a variable disease vary from patient to patient, with some patients requiring different dosing of budiodarone to be therapeutically effective as compared to others.
  • the wearables and methods described herein provide sufficient data to the clinician on an ongoing basis to determine the long-term effectiveness of drugs in treating paroxysmal and persistent AFib.
  • methods that integrate data generated by wearables with a drug that can control long duration AFib and/or reduce AFib burden may allow for more effective treatment of AFib, which is a long-felt need in the art.
  • the ability to determine the long-term effectiveness of a drug may allow for dose- adjusting the patient to effectively achieve control over episodes of long duration of AFib. Treatment Regimens using Budiodarone
  • Budiodarone has been shown to reduce episodes of long duration AFib in patients thereby reducing the risk of stroke and congestive heart failure.
  • budiodarone requires that the clinician monitor each patient for efficacy at a given dose. Such represents a personalized medicine approach to a disease that is treatable by budiodarone.
  • patients who have either paroxysmal or persistent AFib and, who are refractory to one or more prior methods for treating their disease may be candidates for the methods and procedures described herein. Such patients may be screened (qualified) for treatment by determining their baseline AFib burden and/or the number and extent of their long duration AFib episodes. Their baseline may also be used to assess the relative reduction in and/or the complete elimination of these symptoms based on budiodarone therapy and/or to identify patients as non-responders to budiodarone therapy.
  • a method to treat patients with paroxysmal or persistent AFib, wherein said patients are refractory to one or more prior therapies to treat their AFib may comprise: a) selecting a patient who is refractory to the one or more prior methods to treat AFib; b) identifying the number of episodes of long duration AFib and the extent of their AFib burden, wherein the identified number and extent satisfy criteria to qualify the patient for treatment with budiodarone by a clinician; c) fitting said patient with a wearable, wherein said wearable comprises: i) at least one electrode and/or optical sensor that, when the wearable is fitted, continuously or semi-continuously monitors the patient’s heart rhythm; ii) a CPU that collects and stores the heart rhythm data; and iii) a transmission component configured to access the data in the CPU, wherein said transmission component is capable of initiating a communication directly or indirectly to a clinician; d) causing collecting and transmitting of the heart rhythm data directly or indirectly to a
  • a clinician can evaluate a patient’s heart rhythm data over at least 2 weeks, over at least 1 month, over at least 3 months, and/or over at least 6 months and potentially for the remainder of the patient’ s life, to determine the number and/or duration of episodes of long duration AFib; based on that determination assess whether the patient should be placed on budiodarone therapy; and, if so, assess the patient’s response to varying doses of budiodarone.
  • the clinician may initiate dosing of budiodarone at a minimal level of about 200 mg twice a day (bid) and then assess whether that dose is effective in eliminating episodes of long duration AFib.
  • the clinician can review data at the initial dosing level and dose-adjust one or more times, e.g., as necessary to arrive at a dose where the patient is substantially free of and/or is free of episodes of long duration AFib.
  • the incremental increases in dosing can be about 200 mg twice a day. So, in this approach, the dosing can be changed from about 200 mg bid, to about 400 mg bid, or to about 600 mg bid, and so on up to about 800 mg bid and possibly higher if the attending clinician determines that there is a benefit to higher doses.
  • the methods described herein can be conducted either in a unitary device, such as a wearable that can record, store and transmit the heart rhythm data.
  • a unitary device such as a wearable that can record, store and transmit the heart rhythm data.
  • systems of multiple devices can also be used, provided that such systems include: a) a wearable that collects heart rhythm data from a patient diagnosed with either paroxysmal atrial fibrillation and/or persistent atrial fibrillation; b) a CPU that is in communication with the wearable that collects and stores the data; and c) a transmission device that communicates with the CPU and that sends the data directly and/or indirectly to one or more designated recipients.
  • Example 1 is provided to illustrate that the use of a wearable can detect AFib episodes during continuous monitoring of a patient.
  • Examples 2 - 7 establish the utility of budiodarone in the methods described herein.
  • the patients all had surgically implanted pacemakers and as such carried a number of risks associated therewith. See, e.g., Pacemaker, https://www.mayoclinic.org/tests- procedures/pacemaker/about/pac-20384689, (last visited October 26, 2022) which is incorporated herein by reference in its entirety.
  • Example 1 Wearables that Detect AFib in Patients on a Continuous Basis
  • a male patient suffering from non-permanent AFib was fitted with a MCOT wearable device sold by Philips BioSciences, Inc., Best, The Netherlands and commercially available by prescription in the United States.
  • the MCOT device employs PPG coupled with an algorithm to assess heart rhythm and AFib.
  • the MCOT device is configured to wirelessly and seamlessly provide heart rhythm and AFib data to a dedicated computer.
  • FIG. 2 provides a cardiogram obtained during the monitoring period. Of note is that there were 33 separate episodes of AFib detected and recorded each separated by periods of sinus rhythm or other arrhythmias. The specific details of the analysis of the cardiogram are as follows:
  • Heart Rate (minimum/maximum) 48/94 beats per minute
  • This example is a clinical trial evaluation of budiodarone in treating 6 patients with paroxysmal or persistent AFib who previously evidenced episodes of long duration AFib (greater than 24 hours).
  • the patients’ heart rhythm was continuously monitored over a two-week period with a pacemaker, and were treated with different doses of budiodarone.
  • the purpose of this example is to establish whether budiodarone reduces long duration AFib lasting more than 24 hours.
  • Table 3 Table 3
  • This example is a clinical trial evaluation of budiodarone in treating 6 patients with either paroxysmal or persistent AFib who previously evidenced episodes of long duration AFib (greater than 24 hrs).
  • the patients’ heart rhythms were continuously monitored over a twelve- week period with a pacemaker (surgically invasive procedure) and were treated with different doses (2 weeks each) of budiodarone.
  • the patients were under continuous monitoring and constant clinician supervision.
  • the purpose of this example is to establish whether budiodarone treatment can reduce longer duration AFib (AFib episodes lasting more than 24 hours) in a clinical study setting and using a pacemaker to evaluate heart rhythm.
  • AFib AFib episodes lasting more than 24 hours
  • “Number” indicates the number of longer duration episodes of AFib (i.e., having a duration of greater than 24 hours). “Duration” indicates the amount of time during the 2-week period spent in the longer duration indicated in hours and a percentage relative to the baseline measurement. As per the above results, 200 mg b.i.d. was sufficient to treat all patients in the study by eliminating the number of episodes of AFib lasting over 24 hours. In this case, dose escalation was not required to improve patient efficacy as the 200 mg bid doses of budiodarone were sufficient to eliminate these long duration episodes of AFib.
  • Example 4 Reduction of Long Duration AFib (> 5 hours) during a 12 -Week Period
  • This example is a clinical trial evaluation of budiodarone in treating 6 patients with either paroxysmal or persistent AFib who previously evidenced episodes of long duration AFib (greater than 5 hrs).
  • the patients’ heart rhythms were continuously monitored over a twelve- week period with a pacemaker (surgically invasive procedure) and were treated with different doses (2 weeks each) of budiodarone.
  • the patients were under continuous monitoring and constant clinician supervision.
  • “Number” indicates the number of long duration episodes of AFib having a duration of greater than 5 hours. “Duration” indicates the amount of time during the 2 week period spent in the greater than 5 hour duration AFib, indicated in hours and a percentage relative to the baseline measurement.
  • all doses of budiodarone provided significant benefits in reducing both the number and duration of AFib episodes over 5 hours, with both the 200 mg bid and the 600 mg bid providing similar results whereas the results for 400 mg bid were exceptionally better than Off Drug condition, but inferior to the 200 mg bid and the 600 mg bid. Finally, the 800 mg bid performed best. In all doses, the reduction in episodes of AFib of greater than 5 hours were above 85% and the corresponding reduction in AFib burden was above 90%.
  • Example 5 Reduction of Long Duration AFib (> 1 hours) during a 12 -Week Period
  • This example is a clinical trial evaluation of budiodarone in treating 6 patients with either paroxysmal or persistent AFib who previously evidenced episodes of long duration AFib (greater than 1 hour).
  • the patients’ heart rhythms were continuously monitored over a twelve- week period with a pacemaker (surgically invasive procedure) and were treated with different doses (2 weeks each) of budiodarone.
  • the patients were under continuous monitoring and constant clinician supervision.
  • the purpose of this example is to establish whether budiodarone reduces long duration AFib (duration >1 hr) in a clinical study setting using a pacemaker to evaluate the heart rhythm. The results of this analysis are provided in Table 6 below:
  • This example demonstrates a substantial reduction in the number of episodes of long duration AFib (> 1 hrs) over a 2 week period.
  • “Number” indicates a number of long duration AFib episodes during the 2 week period
  • “Duration” indicates a number of hours during the 2 week period sent in the long duration AFib episodes
  • Example 6 Reduction in Episodes of AFib greater than 6 minutes during a Twelve Week Period
  • This example shows the robust nature of budiodarone in reducing both AFib burden and episodes of AFib greater than 6 minutes (0.1 hour) in 6 patients with either paroxysmal or persistent AFib and who previously evidenced episodes of long duration AFib (greater than 1 hr).
  • the patients’ heart rhythm was continuously monitored over a twelve-week period with a pacemaker.
  • the patients were treated with different doses (2 weeks each) of budiodarone.
  • the patients were under continuous monitoring and clinician supervision.
  • the “Number” indicates the number of AFib episodes greater than 6 minutes for all tested patients over the trial period (4 weeks for based line, 2 weeks experimental).
  • the “Duration” in hours indicates the cumulative duration in hours over the trial period that the tested patients were measured in episodes of AFib greater than 6 minutes.
  • AFib episodes of greater than 6 minutes can lead to an increased risk of stroke and/or congestive heart failure.
  • the data in Table 7 evidence that, for all doses of budiodarone tested, the number of episodes of AFib longer than 6 minutes was reduced significantly, and at high concentrations of 600 mg bid or 800 mg bid, these episodes were reduced by more than 80%.
  • Table 8 provides a summary of the fraction of time and the number of hours per week that the patients were in episodes of AFib greater than 6 minutes in duration, on average. The percent time in AFib was reduced by 90% for doses of budiodarone at 600 mg bid and 800 mg bid. Table 8
  • the percent time in AFib for a patient is a critical parameter that directly relates to risk factors for stroke and/or congestive heart failure, especially for patients with high CHA2DS2-VASc scores.
  • Table 8 there was a 76.7% drop in percent time in AFib for patients using 200 mg budiodarone twice a day, which further drops to 90% for patients using 600 mg budiodarone twice a day, and even further drops to 94.8% for patients using 800 mg budiodarone twice a day.
  • Example 7 Measurement of Longest Episodes of AFib during the t welve Week Period
  • This example is a clinical trial evaluation of 6 patients treated with different doses of budiodarone each for a two-week period to determine the longest duration episode of AFib experienced at each dose.
  • the patients’ heart rhythms were continuously monitored over a twelve- week period with a pacemaker.
  • the different doses and results of this evaluation are provided in Table 9 below:
  • the administration of budiodarone according to the present method may be conducted using a pharmaceutical composition comprising from about 1% to 99% of budiodarone and the remainder being a pharmaceutically acceptable excipient, such as corn starch, cellulose, stearic acid, water, or other components.
  • the pharmaceutical composition can be formulated into any form which, by way of example, only, may include one or more of a tablet, a capsule, a powder, and/or another formulation for oral administration; a parenteral administration, such as a solution suitable for one or more of intravenous administration, intramuscular administration, etc.; a suppository and/or enema; cutaneous and/or transdermal preparations, etc.
  • the wearable may be programmable (e.g., by the clinician, the patient, and/or remotely, such as by the central analysis center).
  • the wearable may be programmed to capture the patient’ s heart rhythm data.
  • the data so generated can be interrogated and/or analyzed by the CPU on the wearable and/or can be transmitted to another device for interrogation and/or analysis.
  • One example of programming of the wearable may enable the use of the wearable for monitoring the patient’s heart rhythm and relaying the data directly and/or indirectly to, e.g., a clinician as follows.
  • a USER INTERFACE Step functions for programming AFib monitoring system involving the wearable and relying on information through a network to the attending clinician.
  • the readable display should be made available to the authorized clinician at all times, and only the authorized clinician should be authorized to save data and/or reset the monitoring system after going through one or more of Steps 1-15 below.
  • D. Drug exposure, dose, and/or any other medicaments taken by the patient can be retrieved as needed by the clinician from a patient’s medical records, e.g., by integrating the monitoring system with the patient’s medical records (e.g., electronic medical records).
  • Steps 1 to 14 are the only manual entry required, but step 14 is optimal and can be overridden by the clinician simply pushing Manual Reset Step 15.
  • Step 17 All data may be saved after review by the attending clinician, who may also be authorized to program integration of prior observation periods (Step 17), whether on or off a pharmaceutical to treat AFib including budiodarone.
  • the system is user friendly, the attending clinician only needs to do 4 things each time: 1) enter patient or code to access data, 2) review data display, 3) enter dose of budiodarone in Step 14 if they wish, then 4) Push Manual Reset and Store Data.
  • the attending clinician has access to the stored data and integrates observation periods to compare AFib characteristics on different doses of budiodarone or off-drug (Step 17).
  • Steps 4-13 may be included or excluded in the programming of the wearable (e.g., at the discretion of the clinician), provided that at least one of these steps is included.
  • Steps 4-7 may be performed, and the corresponding data collected, and one or more of Steps 8-13 may be excluded.
  • Steps 4, 5, 8, and 9 may be included, and Steps 5, 6, and 10-13 may be excluded.
  • Steps 4, 5, 10, and 11 may be included, and steps 6, 7, 8, 9, 12, and 13 may be excluded.
  • Steps 4, 5, 12, and 13 may be included and Steps 6-11 may be excluded.
  • the attending clinician may program the wearable according to one or more of Steps 4-13.
  • Embodiment 1-1 A method to assess whether a patient with either paroxysmal or persistent atrial fibrillation (AFib) qualifies for a budiodarone therapy, the method comprising: a) selecting a patient afflicted with paroxysmal or persistent AFib; b) fitting said patient with a wearable, wherein said wearable comprises: i) at least one of an electrode or an optical sensor, wherein the at least one of the electrode or the optical sensor is configured to, when the wearable is fitted on the patient, continuously or semi-continuously monitor a heart rhythm of the patient; ii) a first computing device configured to collect and store heart rhythm data based on the monitored heart rhythm; and iii) a transmission component configured to transmit data based on the heart rhythm data in the first computing device to a second computing device accessible by a clinician; c) causing transmission of the data to the second computing device, wherein the data indicates at least one of a presence of a long duration episode of AFib, an AFib
  • Embodiment 1-2 The method of embodiment 1-1, wherein the first computing device is configured to determine the data based on the heart rhythm data by evaluating the stored heart rhythm data to determine the presence of a long duration episode of AFib and the number of long duration episodes of AFib.
  • Embodiment 1-3 The method of embodiment 1-2, wherein said evaluating is continuous.
  • Embodiment 1-4 The method of any of embodiment 1-2 or embodiment 1-3, wherein said evaluating is also, or alternatively, semi-continuous.
  • Embodiment 1-5 The method of any of embodiments 1-1 to 1-4, wherein the first computing device is programmed to, based on the data, alert at least one of the clinician or the patient of a detected long-duration episode of AFib that places the patient at risk of stroke.
  • Embodiment 1-6 The method according to any of embodiments 1-1 to 1-5, wherein the qualifying said patient for budiodarone therapy comprises determining, based on the data, that the patient meets at least one of the following criteria: a) at least one AFib episode of at least 5 hours duration in a 30-day period or at least two episodes at least 1 hour in duration in a 30-day period coupled with an AFib burden at least 2.5% during the 30-day period; b) at least one AFib episode of at least 5 hours duration in a 30-day period or at least 2 episodes at least one hour in duration in a 30-day period coupled with an AFib burden at least 5% during the 30-day period; c) at least one AFib episode of at least 5 hours duration in a 30-day period coupled with an AFib burden at least 2.5% during the 30-day period; d) at least one AFib episode of at least 5 hours duration in a 30-day period coupled with an AFib burden at least 5% during the 30-day period; e) at least one AFi
  • Embodiment 1-7 The method according to any of embodiments 1-1 to 1-6, wherein the wearable is one or more of a patch, a watch, a wristband, a strap, a ring, or a device that adheres to a body when fitted, and wherein the wearable is configured to measure the heart rhythm and transmit the heart rhythm data directly or indirectly to the second computing device.
  • Embodiment 1-8 The method according to any of embodiments 1-1 to 1-7, wherein the patient is refractory to one or more other methods of treating AFib.
  • Embodiment II- 1 A method of treating a patient diagnosed with either paroxysmal or persistent atrial fibrillation (AFib), the method comprising: administering budiodarone to the patient; wherein the patient was identified for budiodarone treatment based on: a to be identified patient being fit with a wearable, wherein said wearable comprises: at least one of an electrode or an optical sensor, wherein the at least one of the electrode or the optical sensor is configured to, when the wearable is fitted on said to be identified patient, continuously or semi-continuously monitors a heart rhythm of said to be identified patient; a first computing device configured to collect and store heart rhythm data based on the monitored heart rhythm of said to be identified patient; and a transmission component configured to transmit data based on the heart rhythm data of said to be identified patient in the first computing device to a second computing device accessible by a clinician; the data of said to be identified patient being transmitted to the second computing device, wherein the data indicated at least one of a presence of a long duration episode of A
  • Embodiment II-2 The method of embodiment II- 1, wherein the patient identified for budiodarone is refractory to one or more other methods of treating AFib.
  • Embodiment III- 1 A method to assess if a qualified patient on budiodarone therapy should be dose adjusted for or disqualified from a budiodarone therapy, the method comprising: a) selecting the qualified patient; wherein the qualified patient is: on budiodarone therapy comprising treatment with a dose of budiodarone or a pharmaceutical composition comprising budiodarone; and fitted with a wearable, wherein said wearable comprises: i) at least one of an electrode or optical sensor, wherein the at least one of the electrode or the optical sensor is configured to, when the wearable is fitted, continuously or semi-continuously monitor a heart rhythm of the qualified patient; ii) a first computing device configured to collect and store heart rhythm data based on the monitored heart rhythm; and iii) a transmission component configured
  • Embodiment III-2 The method of embodiment III- 1, wherein said dose of budiodarone is at least about 200 mg twice a day.
  • Embodiment III-3 The method according to any of embodiments III- 1 to III-2, wherein said dose of budiodarone is from about 200 mg twice a day to about 800 mg twice a day.
  • Embodiment III-4 The method of embodiment III-3, wherein said dose of budiodarone is selected from about 200 mg twice a day, about 400 mg twice a day, 600 mg twice a day, and about 800 mg twice a day.
  • Embodiment III-5 The method according to any of embodiments III- 1 to III-4, wherein budiodarone is administered as a pharmaceutical composition.
  • Embodiment III-6 The method according to any of embodiments III- 1 to III-5, wherein said monitoring with the wearable is maintained for the responsive patients to confirm that said patients remain responsive.
  • Embodiment III-7 The method of embodiment III-6, wherein said patients who are initially responsive to budiodarone but who later become non-responsive are dose adjusted with budiodarone provided that if said dose adjustment fails to restore the patient budiodarone responsive, the patient is removed from treatment with budiodarone.
  • Embodiment III- 8 The method according to any of embodiments III- 1 to III-7, wherein said responsive patients are placed in a registry that identifies those patients as eligible for treatment with budiodarone wherein a listing in the registry is a requirement for receiving budiodarone.
  • Embodiment III-9 The method according to any of embodiments III- 1 to III-8, wherein the data generated by the wearable is transmitted directly or indirectly to a clinician who can assess a presence or an absence of long duration AFib and optionally the extent of AFib burden to the patient.
  • Embodiment III- 10 The method of embodiment III-9, wherein said data is initially transmitted to a remote laboratory where a qualified health care professional analyzes the data.
  • Embodiment III- 11 The method of embodiment III- 10, wherein said qualified health care professional confirms that the patient is eligible for treatment with budiodarone and provides, to an attending clinician information, information indicating: that said professional has confirmed that the patient is eligible; and one or more of the data or the analysis made by said professional.
  • Embodiment III- 12 The method according to any of embodiments III- 10 to III-
  • said qualified health care professional determines whether a patient responsive to treatment with a given dose of budiodarone remains responsive; and if said qualified health care professional determines that said patient is now non- responsive, said professional provides said determination to an attending clinician, with one or more of: a recommendation to dose adjust the patient to restore the patient’s responsiveness; or a recommendation to terminate the patient’ s treatment with budiodarone if said now non-responsive patient is being treated with a maximum prescribed dose.
  • Embodiment III- 13 The method according to any of embodiments III- 1 to III- 12, wherein the assessing the collected heart rhythm data comprises assessing the collected heart rhythm data that was collected beginning at least 3 days after either budiodarone administration was initiated or dose adjustment of budiodarone was initiated.
  • Embodiment III- 14 The method according to any of embodiments III- 1 to III- 13, wherein the assessing the collected heart rhythm data comprises assessing the collected heart rhythm data that was collected beginning at least 14 days after either budiodarone administration is initiated or dose adjustment of budiodarone is initiated.
  • Embodiment IV- 1 A method for reducing a risk of a patient progressing from paroxysmal AFib to persistent AFib or from persistent AFib to permanent AFib, which method comprises: identifying a patient with either paroxysmal or persistent AFib having an AFib burden of at least 2.5% coupled with at least one episode of long duration AFib over a 4- week period; administering budiodarone to said patient at a dose; monitoring efficacy of said administration and optionally adjusting the dose as needed to achieve a reduction in either or both of AFib burden and long duration AFib, whereupon the risk of progression from paroxysmal AFib to persistent AFib or from persistent AFib to permanent AFib is reduced by said dose adjustment; and maintaining said patient monitoring to confirm continued efficacy of budiodarone.
  • Embodiment IV-2 The method of embodiment IV-1, wherein the method also, or alternatively, comprises one or more of: assessing whether the patient qualifies for a budiodarone therapy according to any of embodiments I-1 to I-8; treating the patient according to any of embodiments II- 1 to II-2; or assessing whether the patient should be dose adjusted for or disqualified from budiodarone therapy according to any of embodiments III- 1 to III- 14.
  • Embodiment V-l A method for reducing a risk of heart failure in a patient diagnosed with paroxysmal AFib or persistent AFib, which method comprises: identifying a patient with either paroxysmal or persistent AFib having an AFib burden of at least 2.5% coupled with at least one episode of long duration AFib over a 4- week period; administering budiodarone to said patient at a dose; monitoring efficacy of said dose administration and optionally adjusting the dose to achieve a reduction in either or both of AFib burden and long duration AFib, whereupon the risk of heart failure in said patient is reduced; and maintaining said patient monitoring to confirm continued efficacy of budiodarone.
  • Embodiment V-2 Embodiment V-2.
  • the method of embodiment V-l wherein the method also, or alternatively, comprises one or more of: assessing whether the patient qualifies for a budiodarone therapy according to any of embodiments I-1 to I-8; treating the patient according to any one of embodiments II- 1 to II-2; or assessing whether the patient should be dose adjusted for or disqualified from budiodarone therapy according to any of embodiments III- 1 to III- 14.
  • Embodiment VI- 1 A method for reducing a risk of stroke in a patient diagnosed with paroxysmal AFib or persistent AFib, which method comprises: identifying a patient with either paroxysmal or persistent AFib having an AFib burden of at least 2.5% coupled with at least one episode of long duration AFib over a 4- week period; administering budiodarone to said patient at a dose; monitoring efficacy of said administration and optionally adjusting the dose as needed to achieve a reduction in either or both of AFib burden and long duration AFib whereupon the risk of stroke in said patient is reduced; and maintaining said patient monitoring to confirm continued efficacy of budiodarone.
  • Embodiment VI-2 Embodiment VI-2.
  • Embodiment VII- 1 A method to treat a patient with paroxysmal or persistent AFib, wherein said patient is refractory to one or more prior methods to treat AFib, which method comprises: a) selecting a patient who is refractory to the one or more prior methods to treat AFib; b) identifying a number of episodes of long duration AFib and an extent of AFib burden in the patient; c) qualifying the patient for a budiodarone treatment at a dosage based on the number of episodes of long duration AFib and the extent of AFib burden; d) fitting said patient with a wearable, wherein said wearable comprises: i) at least one of an electrode or an optical sensor, wherein said at least one of the electrode or the optical sensor, when the wearable is fitted on the patient, continuously or semi-continuously monitor a heart rhythm of the patient; ii) a first computing device configured to collect and store heart rhythm data based on the monitored heart rhythm of the patient; and iii
  • Embodiment VII-2 The method of embodiment VII- 1, wherein the method also, or alternatively, comprises one or more of: assessing whether the patient qualifies for a budiodarone therapy according to any of embodiments I-1 to I-8; treating the patient according to any one of embodiments II- 1 to II-2; or assessing whether the patient should be dose adjusted for or disqualified from budiodarone therapy according to any of embodiments III- 1 to III- 15.
  • Embodiment VIII- 1 A method for reducing a risk that a patient with paroxysmal AFib will transition into persistent AFib, which method comprises: identifying a patient with paroxysmal AFib having an AFib burden of at least 2.5% coupled with at least one episode of long duration AFib over a 4-week period; administering budiodarone to said patient at a dose; monitoring efficacy of said administration and optionally adjusting the dose as needed to achieve a reduction in either or both of AFib burden and long duration AFib whereupon the risk of said transition in said patient is reduced; and maintaining said monitoring the patient to confirm continued efficacy of budiodarone.
  • Embodiment VIII-2 Embodiment VIII-2.
  • Embodiment IX- 1 A method for reducing a risk that a patient with persistent AFib will transition into permanent AFib, which method comprises: identifying a patient with persistent AFib having an AFib burden of at least 2.5% coupled with at least one episode of long duration AFib over a 4-week period; administering budiodarone to said patient at a dose; monitoring efficacy of said administration and optionally adjusting the dose as needed to achieve a reduction in either or both of AFib burden and long duration AFib, whereupon the risk of said transition in said patient is reduced; and maintaining said monitoring the patient to confirm continued efficacy of budiodarone.
  • Embodiment IX-2 Embodiment IX-2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Signal Processing (AREA)
  • Electrotherapy Devices (AREA)

Abstract

Sont divulguées des méthodes permettant de traiter des patients atteints d'AFib par surveillance de leur rythme cardiaque pour déterminer la présence et/ou le nombre d'épisodes de longue durée AFib, et éventuellement l'étendue de la charge AFib. Les patients qui répondent aux exigences de seuil sont qualifiés pour le traitement de l'AFib avec un dosage de budiodarone. La surveillance de patient est poursuivie pour confirmer que le patient est et reste réceptif à une thérapie par budiodarone comprenant l'ajustement de dose du patient pour obtenir une telle thérapie. Ensuite, la surveillance est poursuivie pour confirmer que le patient reste réceptif. Lesdites méthodes permettent le traitement de l'AFib et, de manière correspondante, réduisent ou retardent le risque d'accident cérébrovasculaire et/ou d'insuffisance cardiaque congestive chez le patient traité.
PCT/US2023/060238 2022-01-07 2023-01-06 Méthodes de réduction du risque d'accidents cérébrovasculaires par pharmacothérapie pour réduire le nombre et la durée de fibrillations auriculaires WO2023133510A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263297426P 2022-01-07 2022-01-07
US63/297,426 2022-01-07
US202263334852P 2022-04-26 2022-04-26
US63/334,852 2022-04-26
US17/978,835 US11759640B2 (en) 2022-01-07 2022-11-01 Methods for reducing the risk of strokes by pharmacotherapy to reduce the number and duration of atrial fibrillations
US17/978,835 2022-11-01

Publications (1)

Publication Number Publication Date
WO2023133510A1 true WO2023133510A1 (fr) 2023-07-13

Family

ID=85158787

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/060238 WO2023133510A1 (fr) 2022-01-07 2023-01-06 Méthodes de réduction du risque d'accidents cérébrovasculaires par pharmacothérapie pour réduire le nombre et la durée de fibrillations auriculaires

Country Status (1)

Country Link
WO (1) WO2023133510A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9282908B2 (en) * 2013-01-16 2016-03-15 University Of Vermont Methods and systems for optimizing lesion placement to minimize and treat cardiac fibrillation
US9549912B2 (en) 2009-11-23 2017-01-24 Armetheon, Inc. Methods for treating atrial fibrillation
US20180028086A1 (en) * 2016-07-27 2018-02-01 Medtronic, Inc. Automatic thresholds for atrial tachyarrhythmia detection in an implantable medical device
US20200323459A1 (en) * 2019-04-12 2020-10-15 Cardiac Pacemakers, Inc. Long-duration arrhythmia detection
WO2021163331A1 (fr) * 2020-02-12 2021-08-19 Irhythm Technologies, Inc Moniteur cardiaque non invasif et procédés d'utilisation de données cardiaques enregistrées pour déduire une caractéristique physiologique d'un patient

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549912B2 (en) 2009-11-23 2017-01-24 Armetheon, Inc. Methods for treating atrial fibrillation
US9282908B2 (en) * 2013-01-16 2016-03-15 University Of Vermont Methods and systems for optimizing lesion placement to minimize and treat cardiac fibrillation
US20180028086A1 (en) * 2016-07-27 2018-02-01 Medtronic, Inc. Automatic thresholds for atrial tachyarrhythmia detection in an implantable medical device
US20200323459A1 (en) * 2019-04-12 2020-10-15 Cardiac Pacemakers, Inc. Long-duration arrhythmia detection
WO2021163331A1 (fr) * 2020-02-12 2021-08-19 Irhythm Technologies, Inc Moniteur cardiaque non invasif et procédés d'utilisation de données cardiaques enregistrées pour déduire une caractéristique physiologique d'un patient

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
FLAKER ET AL.: "Asymptomatic Atrial Fibrillation: Demographic Features and Prognostic Information from the Atrial Fibrillation Follow-Up Investigation of Rhythmic Management (AFFIRM) Study", AMERICAN HEART JOURNAL, April 2005 (2005-04-01), pages 657 - 663
GO ET AL., JAMA CARDIOLOGY, vol. 3, no. 7, 2018, pages 601 - 608
HOHNLOSER SHKUCK KHLILIENTHAL J: "PIAF investigators. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial", THE LANCET, vol. 356, no. 9244, 25 November 2000 (2000-11-25), pages 1789 - 94
KIRCHHOF PCAMM AJGOETTE ABRANDES AECKARDT LELVAN AFETSCH TVAN GELDER ICHAASE DHAEGELI LM: "Early rhythm-control therapy in patients with atrial fibrillation", NEW ENGLAND JOURNAL OF MEDICINE, vol. 383, no. 14, 1 October 2020 (2020-10-01), pages 1305 - 16
PACKER DLPICCINI JPMONAHAN KHAL-KHALIDI HRSILVERSTEIN APNOSEWORTHY PAPOOLE JEBAHNSON TDLEE KLMARK DB: "CABANA Investigators. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial", CIRCULATION, vol. 143, no. 14, 6 April 2021 (2021-04-06), pages 1377 - 90
REPORT: MORE THAN 15,000 ADVERSE EVENTS LINKED TO XARELTO, 2016, Retrieved from the Internet <URL:https://markets.businessinsider.com/news/stocks/report-more-than-15-000-adverse-events-linked-to-xarelto-in-2016-1002203317>
SINGER ET AL.: "Temporal Association Between Episodes of Atrial Fibrillation and Risk of Ischemic Stroke", JAMA CARDIOLOGY, vol. 6, no. 12, 2021, pages 1364 - 1369
TURAKHIA M.P. ET AL., CIRC ARRHYTHM ELECTROPHYSIOL, vol. 8, no. 5, 2015, pages 1040 - 7
WOJCIKOWSKI ET AL.: "Photoplethysmographic time-domain heart rate measurement algorithm for resource-constrained wearable devices and its implementation", SENSORS, vol. 20, no. 6, 2020, pages 1783
WOLKOVE NBALTZAN M: "Amiodarone pulmonary toxicity", CANADIAN RESPIRATORY JOURNAL, vol. 16, no. 2, 2009, pages 43 - 8
WYSE DGWALDO ALDIMARCO JP: "A comparison of rate control and rhythm control in patients with atrial fibrillation", NEW ENGLAND JOURNAL OF MEDICINE, vol. 347, no. 23, 5 December 2002 (2002-12-05), pages 1825 - 33

Similar Documents

Publication Publication Date Title
US10694965B2 (en) Non-invasive monitoring of physiological conditions
AU2004305423B2 (en) System and method for processing and presenting arrhythmia information to facilitate heart arrhythmia identification and treatment
Kouakam et al. Inadequate sympathovagal balance in response to orthostatism in patients with unexplained syncope and a positive head up tilt test
US20100268040A1 (en) Method and system for detection of pre-fainting and other conditions hazardous to the health of a patient
US20240033531A1 (en) Methods for Reducing the Risk of Strokes by Pharmacotherapy to Reduce the Number and Duration of Atrial Fibrillations
JP2003290165A (ja) 自律神経系をモニターするための非観血的な装置システムおよびその使用
Ebbehøj et al. Effects on heart rate variability of metoprolol supplementary to ongoing ACE-inhibitor treatment in Type I diabetic patients with abnormal albuminuria
US11419560B2 (en) Method and apparatus for monitoring state of inflammatory bowel disease
US20230181083A1 (en) Cardiac signal qt interval detection
US10463299B1 (en) Systems and methods for monitoring medication effectiveness
US20180055373A1 (en) Monitoring device to identify candidates for autonomic neuromodulation therapy
Fratino et al. Evaluation of nociception in unconscious critically ill patients using a multimodal approach
JP7318160B2 (ja) デバイスによる心房不整脈のモニタリングおよびサーバによる特性評価の非侵襲的方法
Omvik et al. The Norwegian office-, home-, and ambulatory blood pressure study (NOHA)
WO2023133510A1 (fr) Méthodes de réduction du risque d&#39;accidents cérébrovasculaires par pharmacothérapie pour réduire le nombre et la durée de fibrillations auriculaires
CN110584633A (zh) 一种可控药物释放的高血压实时诊疗一体化系统
US20230372284A1 (en) Methods for treating atrial fibrillations
US20210219909A1 (en) Wearable personal healthcare sensor apparatus
Songthawornpong et al. Continuous Monitoring of Vital Signs After Hospital Discharge: A Feasibility Study
WO2024072940A1 (fr) Procédé de surveillance et de traitement d&#39;un trouble
Van Chien et al. Applicability of a novel wearable wireless electrocardiogram monitoring device (Spyder) for arrhythmia detection in patients with suspected cardiac arrhythmias
US20230346234A1 (en) Wearable photoplethysmography device for detecting clinical decompensation based on heart rate variability
US20210393145A1 (en) Multiplexing non-invasive biosensing device for monitoring physiological responses to opioids
Girerd et al. HOW MANY DAYS TO CONFIRM HYPERTENSION USING HOME BOOD PRESSURE MONITORING
Girerd et al. ADVANTAGES AND LIMITATIONS OF USING THE AKTIIA CUFFLESS BRACELET FOR A HYPERTENSION SPECIALIST

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23703119

Country of ref document: EP

Kind code of ref document: A1